Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Methods and Findings in Experimental and Clinical Pharmacology

• Publication date

  1998-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 9646285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid

  2004cited by this paper
• ELEVATED CEREBROSPINAL FLUID TAU LEVELS: IMPLICATIONS FOR THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE

  1996cited by this paper
• Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study.

  1996cited by this paper
• Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment

  1995cited by this paper
• Increased cerebrospinal fluid tau in patients with Alzheimer's disease.

  1995cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

  1995cited by this paper
• Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau.

  1995cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cited by this paper
• Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia.

  1990cited by this paper
• Diagnosis of Alzheimer's disease.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Case Report: Usefulness of Biomarkers for Alzheimer's Disease in Two Cases With Very-Late-Onset Schizophrenia-Like Psychosis

  2021cites this paper
• Biomarkers of Alzheimer's Disease

  2019cites this paper
• Amyloid beta and tau proteins in Alzheimer’s disease and Down syndrome

  2018cites this paper
• Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

  2014cites this paper
• Cerebrospinal fluid biomarkers for neurodegenerative disorders

  2013cites this paper
• Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology.

  2013influential citation
• Cerebrospinal fluid tau protein as a biomarker for severity of spinal cord injury in dogs with intervertebral disc herniation.

  2013cites this paper
• Candidate Bio-Markers of Alzheimer’s Disease

  2013cites this paper
• Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

  2013cites this paper
• Identification of Novel Fluid Biomarkers for Alzheimer's Disease

  2012cites this paper
• CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis

  2012cites this paper
• Biomarkers in patients with idiopathic normal pressure hydrocephalus

  2012cites this paper
• Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

  2012cites this paper
• Validation of ELISA Methods for Quantification of Total Tau and Phosphorylated-Tau181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies

  2011cites this paper
• Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus

  2011cites this paper
• Biomarkers of Alzheimer's disease.

  2009cites this paper
• The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)

  2009cites this paper
• Biological CSF markers of Alzheimer's disease.

  2008cites this paper
• Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease

  2007cites this paper
• Cerebrospinal fluid biomarkers for mild cognitive impairment

  2006cites this paper
• Mild cognitive impairment

  2006cites this paper
• Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

  2006cites this paper
• Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease

  2006cites this paper
• Mild cognitive impairment

  2006cites this paper
• Effects of A-beta immunotherapy and Omega-3 fatty acid administration in Alzheimer's transgenic mice

  2006cites this paper
• Post-translational modifications of tau protein in Alzheimer’s disease

  2005influential citation
• MRI and CSF studies in the early diagnosis of Alzheimer's disease

  2004cites this paper
• Cerebrospinal fluid tau and Aβ42 concentrations in healthy subjects: delineation of reference intervals and their limitations

  2004cites this paper
• Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease.

  2004cites this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cites this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cites this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cites this paper
• CSF markers for incipient Alzheimer's disease.

  2003cites this paper
• CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

  2003cites this paper
• Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

  2003cites this paper
• CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.

  2003cites this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cites this paper
• CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

  2003cites this paper
• Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.

  2003cites this paper
• Biological markers of Alzheimer's disease

  2002cites this paper
• Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease.

  2002cites this paper
• Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

  2002cites this paper
• Aktuelle klinisch-neurochemische Diagnostik der Alzheimer-Krankheit/Current Clinical Neurochemical Diagnosis of Alzheimer’s Disease

  2002cites this paper
• Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment.

  2002cites this paper
• Basic and Clinical Studies on the Measurement of β‐amyloid(1–42) in Cerebrospinal Fluid as a Diagnostic Marker for Alzheimer's Disease and Related Disorders: Multi Center Study in Japan

  2001cites this paper
• CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

  2001cites this paper
• Neuroscientific Basis of Dementia

  2001cites this paper
• Biological markers for differential diagnosis of Alzheimer’s disease and related disorders

  2001cites this paper
• Search for reliable diagnostic markers for Alzheimer's disease

  2000cites this paper
• [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].

  2000cites this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry

  2000cites this paper
• Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type

  2000cites this paper
• Frontotemporal dementia: Pick type

  1999cites this paper